

PATIENT INFORMATION: LAGEVRIO

LAGEVRIO may prevent hospitalization or death in adults who are at high risk for severe illness from COVID-19. It must be taken within 5 days of when COVID-19 symptoms start.

What is LAGEVRIO?

LAGEVRIO (Molnupiravir) is a new medicine used to treat mild-to-moderate COVID-19 in adults (aged 18 and older) who:

- ▶ Have a **positive test** result for COVID-19 viral test
- ▶ Are at **high risk for severe COVID-19** including hospitalization and death, and for whom other COVID-19 treatment options are not accessible or appropriate.

LAGEVRIO is an antiviral medicine that is taken by mouth (by swallowing pills) for 5 days. The course of treatment should be completed, regardless of resolution of symptoms.

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to make LAGEVRIO available during the COVID-19 pandemic. LAGEVRIO is not an FDA-approved medicine in the United States.



Tell your healthcare provider if you:

- are **pregnant**, may become pregnant, or are sexually active with partners who may become pregnant.
- have any **allergies**
- are **breastfeeding** or plan to breastfeed
- have any **serious illnesses**
- are taking any **medicines** (prescription, over-the-counter, vitamins, or herbal products)

Does LAGEVRIO have side effects?

- ▶ LAGEVRIO may cause severe harm to unborn babies (based on information from studies with animals)
- ▶ Allergic reactions may happen in people taking LAGEVRIO
- ▶ The most common side effects are:
 - > Diarrhea
 - > Nausea
 - > Dizziness



If you test positive for COVID-19, **talk to your healthcare provider right away** about treatment options.
A prescription is required for all available treatments.



You can find more information about COVID-19 treatments at <https://www.vdh.virginia.gov/coronavirus/treatments>



Updated April 2022